H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Anavex Life Sciences (AVXL – Research Report) today and set a price target of $42.00. The company's shares closed last Tuesday at $10.65, close to its 52-week low of $9.28. According to TipRanks.com, Selvaraju has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -33.9% and a 17.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Aquestive Therapeutics, and Vallon Pharmaceuticals. Anavex Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $30.40.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-anavex-life-sciences-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Anavex Life Sciences Charts.
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Anavex Life Sciences Charts.